Re ENTA. Thanks for your responses. I listened to the presentation and will now listen to the Q & A. I am not all that negative on FXR as their clinical data should rule the day.
I think the sleeper program, not yet at candidate stage, could be the HBV Core inhibitor program. Could this be a repeat of their HCV efforts?
News 
Market Data 
Discover 
